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ABSTRACT 
 
A certain degree of iron overload (IO) is sometimes seen in subjects with β-
thalassemia trait (βTT), a mild form of non-transfusion-dependent β-thalassemia.  
The pathogenesis is unclear, but recently a population study in Sri Lankan 
children has showed that βTT is characterized by mild hepcidin suppression due 
to increased erythropoietic activity. This data is in accordance with previous 
other studies suggesting  that erythropoietic drive can regulate hepcidin 
production, potentially acting via an erythroid-derived hormone, such as the 
recently identified erythroferrone (ERFE). Hepcidin is the master regulator of 
iron homeostasis which acts by inhibiting dietary iron absorption and iron release 
from macrophages, thus its suppression  leads to an increased of iron availability 
in the body. In βTT patients, hepcidin defect may be further aggravated by genetic 
(i.e. mutations in hemochromatosis genes) or acquired factors (e.g. alcohol abuse 
or non-alcoholic liver diseases).    
Treatment of IO in βTT is problematic, since “standard” large-volume 
phlebotomies are not feasible in mildly anaemic subjects, as well as the lack of 
approval of oral iron chelators and of specific guidelines. Deferoxamine is the 
only approved therapy, but it is poorly applicable because of parenteral 
administration and side effects. Sporadic case reports have suggested the use of 
phlebotomies in βTT patients with IO, but feasibility and efficacy of such 
approach has not been evaluated in patients’ series.  
This study has been designed to better characterize factors involved in the 
development of IO in βTT patients, and to evaluate feasibility and efficacy of 
“mini-phlebotomies” in this condition.  
In our population, a substantial alcohol consumption (>100 g/day) appears a 
common acquired cofactor in βTT patients with IO, while biomolecular analysis 
did not reveal potentially pathogenic variants out of the known H63D and C282Y 
in HFE. Mean hepcidin levels were higher than those observed in the general 
population, suggesting  that the hepcidin response to IO is conserved, while the 
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hepcidin:ferritin ratio was lower than in age- and sex-matched normal 
individuals, in agreement with a relative hepcidin defect  in βTT.  
Fifteen patients started treatment with “mini-phlebotomies”, eleven of them 
have reached the iron depletion and no one experienced a worsening of anaemia 
during the treatment, suggesting mini-phlebotomies as a valuable approach for 
this peculiar category of patients. 
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1. INTRODUCTION 
 
1.1 Beta-thalassemia syndromes 
Beta-thalassemias are a group of hereditary blood disorders characterized by 
abnormalities in the synthesis of the beta globin chains of hemoglobin resulting in 
variable phenotypes ranging from severe anemia to clinically asymptomatic 
individuals [Galanello R et al, 2010]. Three main forms have been described: 
thalassemia major (also called “Cooley’s disease” or “Mediterranean Anemia”), 
thalassemia intermedia, and thalassemia minor (variably referred to as “beta-
thalassemia carrier” or “beta-thalassemia trait”).  
Individuals with thalassemia major usually present within the first two years of 
life with severe anemia, requiring regular red blood cells (RBC) transfusions.  
Thalassemia minor is clinically asymptomatic, with the majority of subjects 
showing only a mild hypochromic microcytic anemia.  
In the middle lies thalassemia intermedia (TI), a condition too mild to be 
considered thalassemia major and too severe to be called thalassemia minor. 
Individuals with TI present later than thalassemia major, have milder anemia 
(with hemoglobin levels ranging between 7 and 10 g/dl), and by definition do not 
require or only occasionally require transfusions. Sometimes, they are completely 
asymptomatic until adult life. While in the past the TI diagnosis was based only 
on approximate clinical and biochemical criteria (such as hemoglobin levels), 
over the past decade, our understanding of thalassemia intermedia has increased 
enormously thanks to advances in molecular investigations [Haddad A et al, 
2014]. This aspect is very important, because it is now clear that TI presents 
pathophysiological mechanisms, clinical presentation as well as complications 
associated with the disease that are different from those of β-thalassemia major 
and minor.  
Thalassemia is among the most common genetic disorders worldwide. It has 
been estimated that about 1.5% of the global population (80 to 90 million people) 
are carriers of beta-thalassemia, with about 60,000 symptomatic individuals born 
annually, the great majority in the developing world [Origa R, 2016]. 
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Beta-thalassemia is prevalent in Mediterranean countries (including Italy), the 
Middle East, Central Asia, India, Southern China, and the Far East, as well as 
countries along the north coast of Africa and in South America. The highest 
carrier frequency is reported in two of the largest Mediterranean islands: Cyprus 
(14%) and Sardinia (10.3%), and in Southeast Asia [Flint J et al, 1998]. The high 
frequency of beta-thalassemia alleles in these regions is most likely related to the 
selective pressure from Plasmodium falciparum malaria. Due to the frequency of 
immigration from these regions in recent decades, the incidence of the 
thalassemias has increased also in other geographical areas. 
Beta-thalassemias are caused by point mutations (more than 200 have been so 
far reported) or, more rarely, deletions in the beta globin gene on chromosome 11, 
leading to reduced (beta+) or absent (beta0) synthesis of the beta chains of 
hemoglobin [Giardine B et al, 2007]. Transmission is typically autosomal 
recessive. A list of common mutations in Mediterranean area according to the 
severity of defect is reported in Table 1. 
 
Table 1: Common types of beta-thalassemia mutations in Mediterranean region. 
β-gene mutation Severity 
-101C>T β++ 
-87C>G β++ 
IVS1-nt1G>A β0 
IVS1-nt6T>C β+/++ 
IVS1-nt110G>A β+ 
IVS1-nt745C>G β+ 
Codon 39 C>T β+ 
Codon 5 –CT β0 
Codon 6 –A β0 
AATAAA to AATGAA β++ 
Codon 27 G>T Hb (Hb β++ 
[Modified from Galanello R et al, 2010] 
β
0
: complete absence of beta globin on the affected allele 
β
+
: residual production of beta globin (around 10%) 
β
++
: very mild reduction in beta globin production 
 
Although the degree of globin chain reduction is determined by the nature of 
the mutation at the beta globin gene located on chromosome 11, several modifier 
genes contribute to differences in disease phenotype. In particular, because the 
main pathophysiological determinant of the severity of the β-thalassemia 
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syndromes is the extent of α/non-α-globin chain imbalance, any factor capable of 
reducing this imbalance results in a lesser degree of α-globin chain precipitation 
and may ameliorate the clinical picture. 
Factors include the presence of silent or mild beta-thalassemia alleles 
associated with a high residual output of beta globin, the coinheritance of alpha 
thalassemia and/or of genetic determinants able to sustain a continuous production 
of gamma globin chains (HbF) in adult life [Galanello R et al, 1998].  
In some instances, heterozygous beta-thalassemia may lead to the thalassemia 
intermedia phenotype instead of the asymptomatic carrier state. Most of these 
patients have excess functional alpha globin genes (alpha gene triplication or 
quadruplication) which increase the imbalance in the ratio of alpha/non-alpha 
globin chain synthesis [Sollaino MC et al, 2009; Origa R et al, 2014]. 
However, the clinical severity of β-thalassemia syndromes is also influenced 
by genetic factors unlinked to globin genes [Origa R, 2016] as well as 
environmental conditions and management.  
Table 2 summarizes genetic basis and clinical manifestations of common β-
thalassemia syndromes. 
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Table 2: Genetic basis and clinical manifestations of common β-thalassemias. 
Features Thalassemia 
Major 
Thalassemia 
Intermedia 
Thalassemia 
Minor 
Genetic 
pathology 
Two β-globin genes 
carrying a severe 
thalassemia 
mutation 
Two β-globin genes 
carrying a 
thalassemia mutation, 
at least one of which 
is mild; one β-globin 
thalassemia mutation 
in combination with 
excess α-globin genes 
(less common) 
One β-globin 
gene carrying a 
thalassemia 
mutation 
Clinical 
manifestations 
Severe anemia 
requiring regular 
transfusions 
beginning in 
infancy; 
splenomegaly and 
bone disease 
depending on 
efficacy of 
transfusion therapy; 
severe iron 
overload 
Mild to moderate 
anemia; relative 
independence from 
transfusions; 
prominent 
splenomegaly and 
bone deformities; 
variable degrees of 
iron overload 
depending on severity 
of anemia and 
transfusion 
requirement 
Mild or no 
anemia, with 
variable 
microcytosis; no 
splenomegaly; no 
bone disease; 
possible iron 
overload in 
presence of 
cofactors 
Severity Lifelong supportive 
care required 
From asymptomatic 
to severely 
symptomatic 
Asymptomatic 
[Modified from Rund D et al, 2005] 
 
Ineffective erythropoiesis and hemolysis together cause the anemia that occurs 
in thalassemia. The reduced amount or absence of beta globin chains result in a 
relative excess of unbound alpha globin chains that precipitate in erythroid 
precursors in the bone marrow, leading to their premature death and hence to 
ineffective erythropoiesis (the bone marrow of patients with thalassemia contains 
five to six times the number of erythroid precursors as does the bone marrow of 
healthy controls, with 15 times the number of apoptotic cells in the 
polychromatophilic and orthochromic stages). Peripheral hemolysis occurs when 
insoluble alpha globin chains induce membrane damage to the peripheral 
erythrocytes. Anemia stimulates the production of erythropoietin with consequent 
intensive but ineffective expansion of the bone marrow (up 25 to 30 times 
 normal), which in turn causes the typical described bone deformities. Prolonged 
and severe anemia and increased erythropoietic drive also result in 
hepatosplenomegaly and extramedullary erythropoiesis.
Figure 1 illustrates the complex chain of events that occurs in erythrocytes, 
resulting in their accelerated peripheral destruction.
 
Figure 1: Pathophysiological mechanisms in beta
The severity of β-thalassemia is related mainly to the degree o
precipitates in the red blood cell precursors, causing both mechanic and oxidative damage 
(ineffective erythropoiesis and hemolysis).
 
1.2 Ineffective erythropoiesis and regulation of iron status
Iron is essential for heme and ir
body but is required in larger amounts for hemoglobin synthesis during terminal 
erythropoiesis. Basal systemic iron homeostasis is maintained primarily by the 
recycling of iron from senescent erythrocytes (a
day) with a small contribution from intestinal absorption (about 1
During times of stress erythropoiesis, iron consumption by the bone marrow can 
increase up to 10-fold [Kim A et al, 2015; Camaschella C et al, 2016]
The primary regulator of systemic iron homeostasis, and thus iron availability 
for erythropoiesis, is hepcidin, a 25
by hepatocytes [Park CH et al, 2001]. Hepcidin acts by binding to ferroportin, the 
 
 
-thalassemias.
f α-globin chain excess, which 
 
 
on-sulfur cluster synthesis in every cell of the 
pproximately 20
-amino-acid peptide hormone that is produced 
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-25 mg every 
-2 mg daily). 
.  
 sole known cellular iron exporter, and causing its internalization and degradation 
within lysosomes [Nemeth E et al, 2004]. As ferroportin is expressed on duodenal 
enterocytes, macrophages and hepatocytes, hepcidin controls the flow of iron 
from gut absorption, rec
(Figure 2). Injecting a single dose of synthetic hepcidin into mice caused a rapid 
and dramatic drop in serum iron. Prolonged hepcidin overexpression in transgenic 
mice resulted in iron
inactivation of the hepcidin gene in mice caused severe iron overload, and 
mutations in the hepcidin gene in humans are associated with juvenile 
hemochromatosis, a particularly severe form of genetic iron ove
2011; Ganz T et al, 2012].
 
Figure 2: Hepcidin has a central role in maintenance of iron homeostasis
Hepcidin synthesis is regulated by multiple stimuli. Intracellular and extracellular iron 
concentrations and inflammation stimulate hepci
erythropoietic activity suppresses hepcidin production. In turn, hepcidin regulates plasma iron 
concentrations by controlling ferroportin concentrations on iron exporting cells including 
duodenal enterocytes, recycling 
 
In anemias with ineffective erythropoiesis such as 
production is suppressed [Pasricha SR et al, 2013; Ramos P et al, 2010; Origa R et 
al, 2007], causing hyperabsorption of diet
iron overload even in the absence of transfusions. Although increased 
ycling of senescent erythrocytes, and cellular iron stores 
-restricted erythropoiesis and iron deficiency. Conversely, 
 
din transcription, whereas increased 
macrophages of the spleen and. liver, and hepatocytes.
β-thalassemia, hepcidin 
ary iron by enterocytes and systemic 
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erythropoietic activity has long been known to suppress hepcidin expression, the 
specific mechanisms and “erythroid regulators” involved are still under 
investigation. Multiple proteins have been proposed to act as hepcidin inhibitors 
and “erythroid regulators”: among them, erythropoietin (EPO) itself, soluble 
transferrin receptor-1 (TFR1), soluble hemojuvelin and hypoxia inducible factor-1 
alpha (HIF1-α) [Camaschella C et al, 2015]. GDF15, a cytokine produced by 
mature erythroblasts, might play some role, as it may partially inhibit hepcidin 
transcription in primary hepatocytes. In addition, it was found in extremely high 
concentrations in the sera of beta-thalassemia patients [Tanno T et al, 2007], 
although this finding might simply reflect the release from ineffective 
erythropoiesis or from hypoxic cells.  
The most recent candidate as regulator of hepcidin expression is the hormone 
erythroferrone (ERFE), a member of the C1q-tumor necrosis factor-related family 
of proteins (Figure 3).  ERFE is an EPO-responsive gene. Mice injected with EPO 
rapidly (within 4 h) increased ERFE mRNA expression by erythroid precursors in 
the bone marrow and spleen through the stress erythropoiesis-related JAK2-
STAT5 signaling pathway. ERFE plays an important role in ensuring iron supply 
during stress erythropoiesis in vivo. ERFE knockout mice failed to suppress 
hepcidin acutely in response to phlebotomy or EPO injections, indicating that 
ERFE is necessary for rapid hepcidin suppression in the setting of increased 
erythroid activity. β-thalassemia intermedia mice had dramatically increased 
ERFE mRNA levels in bone marrow and spleen, as would be expected for a 
condition characterized by high EPO levels and increased number of erythroid 
precursors [Kautz L et al, 2014; Kautz L et al, 2015]. 
 
 Figure 3: 
During stress erythropoiesis, differentiating erythroblasts in the bone marrow and spleen 
rapidly increase ERFE production in an EPO
secreted into the circulation and acts on the liver via an unidentified pathway to repress hepcidin 
production. ERFE-mediated hepcidin suppression in turn increases iron availability for new red 
blood cell synthesis in the bone marrow.
 
1.3 Iron accumulation in beta
In thalassemia major, iron overload is an unavoidable consequence of regular 
transfusions, which provide around 6 to 10 grams of iron per year, because the 
human body lacks a mechanism to excrete excess iron.
The iron loading in patients with non
(NTDT) occurs more slowly than that in patients with thalassemia major, and is 
mainly due to increased intestinal absorption secondary to chronic anemia and 
ineffective erythropoiesis as a consequence of hepcidin suppression. D
on the degree of the ineffective erythropoiesis, bone marrow expansion and 
peripheral hemolysis, the enhanced iron absorption accounts for the accumulation 
of about 2 to 5 grams of iron per year. Although the rate of iron loading is slower, 
patients with NTDT can eventually develop complications similar to those of 
patients with thalassemia major, including hepatic, endocrine and cardiac 
dysfunction, particularly as they advance in age [Origa R et al, 2007; Musallam 
KM et al, 2012]. 
A certain degree of IO is sometimes seen also in subjects with 
trait. The pathogenesis is still unclear, but recently a population study in Sri 
Proposed role of erythroferrone (ERFE)
- and JAK2/STAT5-dependent manner. ERFE is 
 
-thalassemia carriers 
 
-transfusion-dependent thalassemia 
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Lankan children has showed that βTT is characterized by mild hepcidin 
suppression due to increased erythropoietic activity [Jones E et al, 2015].  
Other two recent studies have investigated the relationship between 
erythropoiesis and iron metabolism in β-thalassemia carriers in adult [Guimarães 
JS et al, 2015] and in pediatric age [Sulovska L et al, 2016], through an in-depth 
analysis of multiple selected parameters relating to both erythropoiesis  (EPO, 
soluble transferrin receptor-sTfR and growth differentiation factor 15) and iron 
status (serum iron, ferritin, transferrin saturation and hepcidin). βTT carriers 
showed significant differences for all hematological parameters (hemoglobin 
concentration, RBC counts, MCV), while serum iron, ferritin and transferrin 
saturation levels were similar to those observed in healthy group. Hepcidin level 
was only mildly increased, without achieving statistical significance.  
The Authors, in particular, analyzed the levels of sTfR (that reflects the entity 
of erythropoietic activity) and the hepcidin:ferritin ratio (which represents a 
measure of appropriate response of hepcidin to iron stores): in comparison with 
healthy controls, βTT subjects has a normal to low hepcidin:ferritin ratio (that 
suggests an inappropriate suppression of hepcidin synthesis) and concomitantly 
elevated sTfR (in accordance with an expansion of erythropoiesis). When they 
combine this parameters in the formula (hepcidin/ferritin)/sTfR (utilized to 
explore and quantify the opposing forces, i.e. iron availability and erythropoietic 
activity), the Authors observed that this ratio was reduced in β-thalassemia carrier 
group compared to healthy individuals and it distinguished thalassemia carriers 
from healthy controls. Notably, this finding confirmed a disordered interaction 
between iron metabolism and erythropoiesis in βTT subjects, also suggesting a 
possible greater susceptibility to iron accumulation compared with general 
population. 
Although IO in βTT subjects is itself a quite rare condition, in individual 
patients numerous genetic (e.g.  mutations in hemochromatosis genes) or acquired 
co-factors (e.g. alcohol abuse or non-alcoholic liver diseases) may further 
aggravated the relative hepcidin defect contributing to establish a progressive 
significant iron accumulation (Figure 4). In some cases iron overload results from 
 inappropriate long-term administration of o
diagnostic errors in defining microcytic anemia.
 
Figure 4: Genetic and acquired factors may aggravate hepcidin defect in 
Multiple factors may aggravate hepcidin defect in 
[Tan TC et al, 2012], alcohol abuse [Dostalikova
infection [Girelli D et al, 2009], hemochromatosis
Dijk BA et al, 2008; Papanikolaou G et al, 2005], and 
testosterone [Bachman E et al, 2010; Guo W et al, 2013] and estrogens [Yang Q et al, 2012; 
Lehtihet M et al, 2016].  
 
Concerning hereditary factors, their role is still not well defined. Variants on 
“hemochromatosis genes
receptor 2 and ferroportin) could theoretically contribute to iron accumulation 
worsening the hepcidin defect. Although hereditary hemochromatosis (HH) is 
typically an autosomal recessive disorder and need
develop, in β-thalassemia carriers is possible that even single mutations or 
polymorphisms may contribute to the iron accumulation. However, to date, a 
limited number of reports have specifically addressed this issue, with partial
conflicting results: some suggested that iron overload might arise from the 
interaction of the beta
some with homozygosity for 
hemochromatosis [Arruda VR et al, 2000; 
ral or even parenteral iron, because of 
 
βTT patients, such as chronic liver d
-Cimburova et al, 2014], hepatitis C virus (HCV) 
-related mutations [Girelli D et al, 2011; van 
administration of the sex hormones 
” (such as HFE, hemojuvelin, hepcidin, transferrin 
s of a double mutation to 
-thalassemia trait with heterozygosity for hemochromatosis, 
hemochromatosis, and others that it was unrelated to 
Piperno A et al, 2000; Melis MA et al, 
16 
 
βTT. 
iseases 
ly 
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2002; Martins R et al, 2004; Garewal G et al, 2005; Yamsri S et al, 2007; Madani 
HA et al, 2011; Nadkarni AH et al, 2016]. As shown in Table 3, these studies are 
markedly different each other and result difficult to compare. 
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Table 3: Principal studies evaluating the combined effects of βTT and HFE variants on iron status. 
Reports Aim of the study Results/ 
Discussion 
Piperno et al. 
2000 
To analyze phenotype, iron indices and HFE 
genotypes of 22 patients with the βTT who met the 
phenotypical criteria for HH (assessed by serum 
iron indices and liver iron concentration). To 
compare serum iron indices in relatives 
heterozygous for the C282Y mutation with and 
without the βTT. 
βTT aggravates the clinical picture of C282Y homozygotes, 
favouring higher rates of iron accumulation and the development 
of severe iron-related complications. Association of the βTT with 
a single C282Y or H63D allele seems to not lead to iron overload.  
Arruda et al. 
2000 
To describe modification of ferritin and transferrin 
saturation (TS) in one family comprising subjects 
C282Y mutation on HFE in homozygosis or 
heterozygosis, with and without βTT. 
The propositus (female, 38 years old), homozygous for the C282Y 
mutation and heterozygous for β-thalassemia, presented a very 
high serum ferritin level, uncommon for patients at this age. Her 
mother, who carried βTT and C282Y mutation, presented a level 
of ferritin and TS slightly above the normal. On the contrary, her 
father, who does not present the βTT but is heterozygous for the 
C282Y mutation, did not have abnormal levels of ferritin or TS. 
Melis et al. 
2002 
To evaluate the effect of the H63D mutation on the 
ferritin levels in 152 healthy males heterozygous for 
β-thalassemia (45 subjects heterozygous for H63D 
variants, 4 subjects homozygous for H63D). 
Only the homozygous state for H63D is able to produce 
statistically significant higher levels of ferritin in βTT carriers. 
 
Martins et al. 
2004 
To evaluate the effect of HFE mutations (C282Y, 
H63D, and S65C) on the iron status of βTT carriers 
(n=101) compared with controls (n=101). 
H63D mutation, even when present in heterozygosity, may 
increased serum iron and TS in βTT carriers. The number of 
subjects carrying C282Y or S65C mutations was too low to 
conclude their effect on the iron status.  
Garewal et al. 
2005 
To correlate C282Y and H63D mutations with the 
iron status in 215 βTT carriers. 
All individuals were wild-type for the C282Y variant. No 
statistically significant difference in ferritin levels and TS was 
19 
 
detected between the individuals of the wild-type and mutant for 
H63D. 
Yamsri et al. 
2007 
To determine the prevalence of the H63D mutation 
in 370 Thai thalassemia carriers and 201 normal 
subjects and to evaluate its influence on ferritin 
level. 
The H63D heterozygosity was identified in 5.5% of normal 
subjects and 7.3% of βTT carriers. The H63D heterozygosity has 
no significant effect on the serum ferritin in both groups. 
Madani et al. 
2011 
To determine the prevalence of C282Y, H63D and 
S65C mutations of HFE gene in βTT and 
investigate their influence on TS, comparing them 
with individuals without thalassemias. 
H63D, S65C and C282Y allele frequencies were 30.5%, 13.4% 
and 7.3% respectively in βTT and 10.0%, 2.5% and 0.0% 
respectively in the control group. 8 patients had TS >45% (7 males 
and 1 female). Of these, 6 were heterozygous for H63D, S65C and 
C282Y, 1 patient was heterozygous for H63D and S65C and 1 
patient was homozygous for H63D. 
Nadkarni et al. 
2016 
To look at the effect of HFE mutations on the iron 
status (ferritin level). A total of 100 βTT patients 
and 100 normal individuals were screened for the 
C282Y and H63D mutations on HFE.  
βΤΤ with H63D genotype showed higher ferritin levels as against 
wild type genotype. The study suggests that iron load in βTT tends 
to aggravated with the co-inheritance of the H63D mutation, even 
when present in heterozygosity. 
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1.4 Treatment of iron overload in beta-thalassemia carriers 
Treatment of IO in βTT is problematic, since “standard” large-volume 
phlebotomies (400-450 ml) are not feasible in mildly anemic subjects. The use of 
the oral iron chelator deferasirox, although has been approved in the treatment of 
patients with non-transfusion dependent iron loading anemias, is not supported by 
extensive scientific evidence in patients with βTT and in some cases is burdened 
with serious complications such as acute renal failure. 
Deferoxamine (DFO), available in clinical practice for nearly 50 years, remains 
therefore the iron chelator currently most used in βTT carriers with IO, but it is 
poorly applicable because of inconvenient parenteral administration and side 
effects. DFO is a large hexadentate iron chelator, with a low oral availability and a 
short half-life (approximately 20 min), that requires a parenteral administration, 
usually as a slow subcutaneous infusion via a portable pump for a period of 8-12 
hours 5-7 nights per week. Average dosage is 20-40 mg/kg body weight for 
children and 30-50 mg/kg body weight for adults. The most frequent adverse 
effects of DFO are local reactions at the site of infusion, such as pain, swelling, 
induration, erythema, burning, pruritus, wheals and rash, occasionally 
accompanied by fever, chills and malaise. Other complications are sensorineural 
hypoacusia, ocular toxicity and infections by Yersinia Enterocolitica, and other 
pathogens like Klebsiella Pneumoniae. It is therefore important to monitor 
patients receiving DFO regularly with audiometric and ophthalmologic tests. 
However, because of the side effects and the inconvenient parenteral 
administration, a consistent proportion of patients is non-compliant, limiting the 
usefulness of this chelator, particularly in asymptomatic patients. 
Sporadic case reports have suggested the use of phlebotomies in βTT patients 
with IO, but feasibility and efficacy of such approach has not been evaluated in 
patients’ series. De Gobbi and colleagues, in particular, described the case of a 
young Italian female with juvenile hemochromatosis who was unable to tolerate 
frequent phlebotomy because of coexistent βTT. As an alternative to iron 
subcutaneous chelation, the patient was successfully iron-depleted by combining 
phlebotomies (350 ml) with recombinant human erythropoietin [De Gobbi M et 
al, 2000]. 
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1.5 Aims of the study 
This study has been designed to better characterize factors involved in the 
development of relevant IO in βTT patients, and to evaluate feasibility and 
efficacy of phlebotomies to remove IO in this condition. Given the potential risks 
associated with the use of erythropoietic-stimulating agents (ESAs) and the lack 
of specific guidelines, we have opted for a pioneering approach based on the use 
of "mini-phlebotomies" of 150-250 ml, without the addition of ESAs. 
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2. PATIENTS AND METHODS 
 
2.1 Patients enrollment, blood sample collection and analysis 
Until now, the study included 32 beta thalassemia carriers, referring to the 
Regional Referral Center of Iron Disorders of Azienda Ospedaliera Universitaria 
Integrata of Verona (Italy). The recruitment of subjects is still ongoing. The study 
was approved by the local ethical committee. All subjects released a written 
informed consent for hepcidin measurement and DNA analysis. The subjects were 
selected, since 1999, from outpatients who were referred to us for abnormalities of 
serum iron parameters. 
Fasting blood samples were obtained in the early morning. Serum was obtained 
after centrifugation; if not analyzed immediately, samples were aliquoted and 
stored at -80°C for further analysis. Blood cell counts and erythrocyte indexes 
were determined with an automated cell counter. Other blood tests, serum iron, 
transferrin, and ferritin were determined by standard methods. For our study, the 
normal ranges we established for ferritin, serum iron and ST were 30–300 ng/ml, 
55–160 µg/dl and 20–40%, respectively. 
Hepcidin analysis was performed using an updated and validated Mass-
Spectrometry (MS)-based assay, which is able to dissect the iron bioactive 
hepcidin-25 from other hepcidin isoforms [van der Vorm LN et al, 2016]. We 
used a liquid chromatography tandem mass spectrometry (LC-MS/MS) approach 
[Wolff F et al, 2013]. Briefly, hepcidin-25 synthetic standards (native and the 
isotopic labeled internal standard), as well as standards for hepcidin-20 and 
hepcidin-24 isoforms, were purchased from Peptide International (Lousiville, 
USA). Internal standard was added in all samples and calibration curve. Blank 
serum (deprived of hepcidin by using charcoal treatment) was used as reference. 
Samples were treated by solid phase extraction using Oasis hydrophilic-lipophilic 
balanced reversed-phase (HLB) cartridges (Waters, Italia). High Performance LC 
was performed using an X-Terra MS C18 2.5 Lm column (Waters, Italia), and 
detection was obtained using a Triple Quad LC MS/MS (Agilent Technologies). 
Results were evaluated according to previously obtained reference ranges (as 
reported in Table 4), for males and females at different ages [Traglia M et al, 
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2011]. The lower limit of detection of hepcidin with this method is 0.55 nM. In 
order to produce comparable results and to override the circadian rhythm of 
hepcidin [Ganz T et al, 2008; Kroot JJ et al, 2009] measurements were performed 
on samples obtained in all cases after an overnight fast. 
 
Table 4: Normal values of hepcidin-25 (nM) according to sex and age.  
Age class (years) Males Females 
18-29 11.3 (1.3)* 4.4 (0.4) 
30-39 11.8 (0.9) 4.7 (0.4) 
40-49 11.4 (0.8) 4.7 (0.4) 
50-59 10.8 (0.7) 11.1 (0.9) 
60-69 11.8 (0.9) 11.6 (0.7) 
70-79 11 (0.9) 10.2 (0.9) 
≥80 10.6 (1.3) 8.6 (1.8) 
*Reference values expressed as mean ± standard deviation  
 
The DNA samples were used for Next Generation Sequencing (NGS)-based 
test of the five gene involved in Hereditary Hemochromatosis (HFE, hemojuvelin 
[HJV], hepcidin [HAMP], transferrin receptor 2 [TfR2] and ferroportin 
[SLC40A1]) and of other 65 genes involved in iron homeostasis (e.g. 
BMP/SMAD1/5/8-signaling complex involved in hepcidin encoding gene 
expression) using IlluminaHiSeq 1000 platform, available at the Interdepartmental 
Functional Genomic Facility Centre of the University of Verona. Results were 
analyzed by the GoldenHelix™ method software [for details see Badar S et al, 
2016]. 
Finally, serum ERFE concentration will be soon measured by the team of 
professor Nemeth in Los Angeles (the human assay for its measurements is 
currently under development).  
 
2.2 Assessment of βTT carriers 
The recognition of βTT carriers was based on hematological tests. The 
presence of a very low mean corpuscular volume (MCV) of red blood cells (RBC) 
with concomitant increased RBC number, with or without a mild anemia, 
suggested the diagnosis of βTT. All patients had a family history for microcytic 
anemia and, in some of them, we confirmed the presence of heterozygosis for a β-
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gene mutation by a molecular test (PCR-based procedure) (genetic test for beta-
thalassemia mutations is still in progress in other subjects). 
 
2.3 Assessment of iron overload 
Iron accumulation was firstly suggested by high ferritin levels (often higher 
than 1000 microgram per liter) and, in most cases, by high transferrin saturation 
and then confirmed by liver biopsy or magnetic resonance imaging (MRI).  
Although raised levels of ferritin often indicate iron overload, they are not 
specific, as ferritin is an acute phase reactant and is also released from damaged 
hepatocytes; thus levels are elevated in inflammatory disorders, liver diseases, 
alcohol excess, or malignancy. Raised ferritin levels therefore require further 
investigation to determine if they truly represent iron overload. This can usually 
be confirmed through clinical assessment and measurement of serum transferrin 
saturation. 
Moreover, serum ferritin levels seem to underestimate iron load in non-
transfused thalassemia patients compared with transfusion-dependent patients. 
Some studies [Taher et al, 2009; Origa et al, 2007], in particular, found that serum 
ferritin was significantly lower in patients with thalassemia intermedia than in 
those with thalassemia major, despite the liver iron concentration being 
comparable. Lower serum ferritin in thalassemia intermedia reflects iron 
accumulation predominantly in hepatocytes rather than in macrophages, as 
observed by Perls’ stain. This phenotype is likely the consequence of hepcidin 
deficiency. Hepcidin deficiency likely allows greater export of iron from 
macrophages, thus lowering macrophage cytoplasmic iron and suppressing 
secretion of soluble ferritin.  
Although there are no studies that have specifically investigated the correlation 
between ferritin and iron accumulation in βTT carriers, it is conceivable that this 
last condition is more similar to that of TI than TM, being characterized by 
relatively suppressed hepcidin levels. It was therefore not excluded that ferritin 
tends to underestimate the actual iron deposits even in the βTT carriers. 
Determination of liver iron concentration in a liver biopsy specimen shows a 
better correlation with total body iron accumulation and is considered the gold 
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standard for the evaluation of iron overload. Liver sections were stained with 
standard methods for histological evaluation and with Perls’ stain for iron grading. 
However, liver biopsy is an invasive technique with the possibility (though low) 
of complications. Moreover, the presence of hepatic fibrosis or cirrhosis and 
heterogeneous liver iron distribution can lead to possible false negative results.  
In recent years, nuclear magnetic resonance imaging (MRI) techniques for 
assessing iron loading in the liver (and heart) have been introduced. R2 and T2* 
parameters have been validated for liver iron concentration. In our patients, liver 
iron concentration (LIC) assessed by MRI was calculated by Gandon’s algorithm 
(available on www.radio.univ-rennes1.fr) [Gandon Y et al, 2004]. In clinical 
practice, values less than 36 µmol Fe/g represent the physiological condition. 
Values less than 100 µmol Fe/g are indicative of mild iron overload while values 
greater than 200 µmol Fe/g suggest severe overload. The method, however, have 
some limitations: a) it saturates with very high iron overload and does not give a 
value of LIC higher than 350 µmol Fe/g [Alústiza Echeverría et al, 2012], b) has a 
tendency to overestimated iron overload [Castiella A et al, 2011] and c) is 
influenced by the presence of steatosis. 
 
2.4 Therapeutic approach with “mini-phlebotomies” and calculation of iron 
removed 
Traditional treatment by phlebotomy was unfeasible in our patients with mild 
anemia. As an alternative to iron chelation with DFO, in some selected patients 
we started a pioneering approach with “mini-phlebotomies” (150-250 ml). 
Frequency and amount of phlebotomies were established by the colleagues of the 
transfusion center and personalized based on the individual characteristics of each 
patient, in terms of hematological and clinical tolerability to the treatment. 
In the presence of a normal value of hematocrit (around 45% for males and 
43% for females), 1 ml of blood contains about 0.5 mg of iron. Calculating the 
mean blood hematocrit in patients with βTT, we hypothesized that is possible, 
although approximately, to estimate the amount of iron removed for each ml of 
blood taken during venesection in these mild anemic patients, according to the 
following proportion: 
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Iron removal in 1 ml blood (Ht 45%) = 0.5 mg Fe 
normal Ht% : mean Ht% in βTT = 0.5 mg Fe: X mg Fe 
 
Finally we calculated total iron removed multiplying the amount of iron 
estimated in each ml of blood and the total volume of blood removed at the end of 
venesection. 
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3. CRITICAL RESULTS 
 
3.1. Clinical, biochemical, molecular data and iron status 
Currently the study includes 32 subjects (25 males and 7 females), aged 23-80 
years (mean age 59 years). The majority of subjects comes from Northern Italy. 
The mean values of hemoglobin were not uniform, in agreement with the known 
phenotypic variability of the β-thalassemic trait (Table 5). 
 
Table 5: General characteristic of population sample and hematological data. 
Patients Sex Age 
(years) 
Origin Mean Hb 
(g/dl) 
β-gene mutation 
1 M 54 Verona 12-13 n.a. 
2 M 57 Verona 12-13 Codon 39 C>T  
3 M 61 Rovigo 12-13 n.a. 
4 M 40 Verona 12-13 n.a. 
5 M 50 Verona 9.5-10.5 n.a. 
6 M 59 Verona 13-14 n.a. 
7 F 47 Verona 10-11 n.a. 
8 M 52 Padova 11-12 n.a. 
9 F 55 Verona 10-11 Codon 39 C>T  
10 M 46 Verona 10.5-11.5 Codon 39 C>T  
11 M 64 Verona 11.5-12.5 Codon 39 C>T  
12 M 70 Verona 12-13 n.a. 
13 F 64 Verona 10-11 Codon 39 C>T  
14 M 80 Verona 14-15 n.a. 
15 M 64 Verona 12.5-13.5 n.a. 
16 M 64 Verona 11.5-12.5 Codon 39 C>T  
17 M 65 Mantova 11-12 n.a. 
18 M 48 Verona 11.5-12.5 IVS 2.745 C>G 
19 M 75 Verona 11-12 Codon 39 C>T 
20 M 60 Cagliari 12-13 n.a. 
21 F 69 Napoli 10-11 n.a. 
22 M 60 Treviso 13-14 IVS 1-nt110 G>A 
23 F 46 Venezia 10.5-11.5 n.a. 
24 M 56 Venezia 13-14 n.a. 
25 M 23 Rovigo 13-14 n.a. 
26 M 54 Verona 11-12 n.a. 
27 M 65 Verona 12-13 n.a. 
28 M 46 Trento 10-11 n.a. 
29 M 75 Verona 12-13 n.a. 
30 M 69 Verona 10.5-11.5 IVS 1.1 G>A 
31 F 79 Verona 10-11 n.a. 
32 F 67 Rovigo 11.5-12.5 n.a. 
M: male; F: female; n.a.: not available 
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All subjects had high level of ferritin, detected in multiple determinations, and 
most of them had transferrin saturation higher than normal. No patient had clinical 
or biochemical signs of acute or chronic inflammation, while in approximately 
40% there was a mild increase of transaminases due to coexistent chronic liver 
disease. 14 patients underwent to liver biopsy for diagnostic and/or prognostic 
aim. Liver iron concentration (LIC) was available in 20 subjects and was 
measured by quantitative magnetic resonance (MRI) as previously reported. 
Combining these data (high ferritin levels, TS>40%, LIC-MRI>36 µmol/g 
and/or liver biopsy), we confirmed the presence of IO in 30/32 βTT carriers 
(Table 6). In 2 subjects (12 and 27, indicated by the arrows) we did not have 
enough elements to determine if the increase of ferritin levels was actually 
correlated to the presence of iron accumulation. 
 
Table 6: Biochemical, imaging and histological data of population sample. 
Patients Ferritin 
(ng/ml) 
TS 
(%) 
AST/ALT 
(U/l) 
LIC-
MRI 
(µmol/g) 
Liver 
Biopsy 
Perls’ staining IO 
1 944 54 n.a. n.a. S Hep. (3+) + Kupf. yes 
2 962 55 ↑ n.a. S+C Hep. (2+) + Kupf. yes 
3 1060 41 normal 150 FLH Hep. (2+) + Kupf. yes 
4 993 43 ↑ 60 n.a. n.a. yes 
5 2542 100 ↑ >350 n.a. n.a. yes 
6 691 19 normal 50 n.a. n.a. yes 
7 735 28 normal 150 n.a. n.a. yes 
8 1378 100 ↑ n.a. H+F Hep. (4+) yes 
9 699 46 normal 330 S Hep. (3+) + Kupf. yes 
10 947 100 ↑ 150 FLH+F Hepatoc. (3+) yes 
11 1146 53 normal 270 S+C Hep. (3+) + Kupf. yes 
12 729 36 n.a. n.a. n.a. n.a. no 
13 848 65 normal n.a. n.a. n.a. yes 
14 894 52 normal n.a. n.a. n.a. yes 
15 644 40 normal 95 n.a. n.a. yes 
16 620 52 normal 170 n.a. n.a. yes 
17 1215 46 ↑ 170 n.a. n.a. yes 
18 3087 98 ↑ 290 n.a. n.a. yes 
19 454 66 normal 200 n.a. n.a. yes 
20 1125 25 ↑ 65 FLH+F Hep. (1+) + Kupf. yes 
21 840 77 ↑ n.a. C Hepatoc.  yes 
22 3650 87 normal n.a. F Hep. + Kupf. yes 
23 994 88 ↑  n.a. F Hep. (4+) + Kupf. yes 
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24 3100 78 normal n.a. C Hep. (3+) yes 
25 899 77 ↑ 65 FLH+F Kupf. yes 
26  893  80 normal  55  n.a. n.a. yes 
27 450 26 normal n.a. n.a. n.a. no 
28 880 45 ↑ 270 H+F Hep. (3+) + Kupf. yes 
29 1195 58 normal 250 n.a. n.a. yes 
30 2642 91 ↑ 210 n.a. n.a. yes 
31 841 61 ↑ n.a. n.a. n.a. yes 
32 3015 70 normal 230 n.a. n.a. yes 
TS: transferrin saturation. AST/ALT: aspartate and alanine transaminases. IO: iron overload. 
WT: wild type. S: steatosis. C: cirrhosis. FLH: fatty liver hepatitis. H: hepatitis (inflammatory 
damage). F: fibrosis. (°): after venesection.  
 
As concern genetic factors potentially aggravating iron overload, we observed 
that four subjects carried a significant double mutation on HFE-gene 
(C282Y/H63D in patient 13 and C282Y/C282Y in patients 22, 23 and 24), while 
in most patients we found only the H63D variant (in homo- or heterozygosis) 
whose role in iron overload remains controversial. 
Regarding acquired factors such as alcohol intake, considered that scientific 
communities in different countries agreed that “moderate” consumption of alcohol 
comprises about 15 g/day for women and 30 g/day for men (corresponding to 1–3 
glasses per day of wine, containing 12–14% alcoholic fraction) [Biasi F et al, 
2014], most of our subjects had a very high consumption of alcohol (about 28% 
declared a current or past alcohol consumption higher than 100 g per day and 12% 
around 60 g/day). One patient (subject 7) had been transfused with 30 U of RBCs 
in 1989 after a diagnosis of acute myeloid leukemia. Two patients (31 and 32) had 
been treated with prolonged parenteral iron therapy. Three subjects (18, 21 and 
31) had a chronic hepatitis C infection.  
Finally, about 31% of subjects showed at least two components of metabolic 
syndrome and 47% presented at least one component. The role of metabolic 
syndrome in the determinism of iron overload has been debating for a long time  
[Mendler MH et al, 1999; Riva A et al, 2008], however its presence represents an 
indisputable confounding factor in the interpretation of serum indices: 
hyperferritinemia with normal or mildly elevated transferrin saturation, in fact, is 
observed in approximately one-third of patients with non-alcoholic fatty liver 
disease (NAFLD) or metabolic syndrome and iron perturbations are frequently 
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observed in patients with obesity, insulin resistance or NAFLD [Datz et al, 2013; 
Datz et al, 2017]. This condition has been named the “dysmetabolic iron overload 
syndrome (DIOS)”. 
Table 7 summarizes main genetic and acquired factors potentially aggravating 
iron overload in our patients.  
 
Table 7: Hereditary and acquired risk factors for iron accumulation. 
Patients HFE-
mutation 
Alcohol intake 
per day 
Other acquired 
factors 
Met Syn 
1 H63D +/- 100 g - H + D 
2 H63D +/- 100 g (until 1994) - - 
3 WT 60 g - O 
4 WT 60 g - DM+D+U+O 
5 H63D +/- 100 g (until 1998) - D 
6 WT - - I+D+IFG 
7 n.a. - RBC transfusion - 
8 WT 60 g - - 
9 H63D +/- - - - 
10 WT - - D + U 
11 H63D +/+ 150 g - - 
13 C282Y/H63D - - - 
14 WT - - U + D 
15 WT - - H + O 
16 WT 150 g - O 
17 WT 100 g (until 2013) - - 
18 WT > 100 g HCV infection - 
19 WT 60 g - - 
20 H63D +/- - - H+O 
21 H63D +/- - HCV infection - 
22 C282Y +/+ - - H 
23 C282Y +/+ - - - 
24 C282Y +/+ - - H+O 
25 WT - - IFG+U+O 
26 H63D +/-  125 g (until 2013) -  IFG+O 
28 H63D +/- - - - 
29 WT 200 g (until 2015) - - 
30 WT - - - 
31 WT - parenteral iron + 
HCV infection 
H 
32 WT - parenteral iron - 
Met Syn: Metabolic Syndrome factors. H: Hypertension. DM: Diabetes Mellitus. IFG: 
Impaired Fasting Glucose. D: Dyslipidemia. U: High Uric Acid. O: Overweight (body mass index 
>25 kg/m2 and < 30 kg/m2). RBC: red blood cells. HCV: hepatitis C virus. 
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The serum from 23/30 patients with IO was used for hepcidin determination by 
a Mass-Spectrometry (MS)-based assay (Table 8).  
 
Table 8: Hepcidin level (nM) by mass spectrometry-based method. 
Patients Sex Age Hepcidin (nM)  Patients Sex Age Hepcidin (nM) 
2 M 57 7.20   17 M 65 14.83 
4 M 40 11.80 18 M 48 6.10 
5 M 50 33.00 20 M 60 13.98 
6 M 59 22.60 21 F 69 1.87 
7 F 47 23.90 22 M 60 < 0.55 (°) 
8 M 52 4.70 23 F 46 3.58 
9 F 55 6.90 24 M 56 < 0.55 (°) 
10 M 46 6.40 28 M 46 12.37 
11 M 64 11.80 29 M 75 28.00 
13 F 64 14.90 30 M 69 22.80 
15 M 64 15.40 32 F 67 20.20 
16 M 64 13.00     
(°) after venesection 
 
Figure 5 represent serum hepcidin levels in our βTT patients as compared to 
age- and sex-dependent hepcidin variations in a large sample of normal 
individuals [Traglia M et al, 2011].  
 
 Figure 5: Serum hepcidin levels in our 
males; square = females) as compared to age
variations in a large sample of normal individuals. In the red square are indicated 
the patients with hepcidin levels lower than normal.
 
In our population, 14/23 subjects had mean hepcidin levels higher than those 
observed in the general population, suggesting a certain degree of conservation of 
the hepcidin response to IO, while 7/23 subjects had mean hepcidin levels lower 
than normal. Hepcidin levels of patients 22 and 24 were not considered, because 
they were dosed after vene
Table 9 summarizes clinical, biochemical, genetic and histological 
characteristics of 7 subjects with hepcidin suppression. In particular, subject 23 
had homozygous C282Y mutations on HFE gene, subject 2 
a previous very high 
HCV infection, subject 18 had high alcohol intake and a HCV
with a severe impairment of liver synthetic function.
Other patients (subjects 8, 9, 10) apparently did not exhibit sign
aggravating factors for hepcidin defect but 
βTT patients with IO (diamond = 
- and sex-dependent hepcidin 
 
section.  
had H63D variant and 
alcohol intake, subject 21 had H63D variant and a chronic 
-
 
had clinical-
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related cirrhosis 
ificant 
biochemical or 
33 
 
histological characteristics indicating a possible non-HFE hereditary 
hemochromatosis.  
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Table 9: Clinical, biochemical, genetic and histological characteristics of 7 subjects with hepcidin suppression.  
Patients Sex Ferritin 
(ng/ml) 
TS 
(%) 
HFE 
mutations 
Acquired factors LIC-MRI 
(µmol/g) 
Perls’ staining at liver 
biopsy 
2 M 962 55 H63D +/- daily alcohol intake of 100 g (until 1994) n.a. Hepatoc. (2+) + Kupffer 
8 M 1378 100 WT daily alcohol intake of 60 g n.a. Hepatoc. (4+) 
9 F 699 46 H63D +/- - 330 Hepatoc. (3+) + Kupffer 
10 M 947 100 WT - 150 Hepatoc. (3+) 
18 M 3087 98 WT daily alcohol intake of  >100 g + HCV 
infection with liver cirrhosis 
290 n.a. 
21 F 840 77 H63D +/- HCV infection n.a. Hepatoc. 
23 F 994 88 C282Y +/+ -  n.a. Hepatoc. (4+) + Kupffer 
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On the other hand, the hepcidin:ferritin ratio (Table 10), that reflects the 
response of hepcidin to iron stores concentrations, was lower in our βTT patients 
than in age- and sex-matched normal individuals, in agreement with a relative 
hepcidin defect  in βTT. 
 
Table 10: Hepcidin:ferritin ratio (pmol/g) in our population. 
Patients Sex Age Hep:ferr 
ratio 
 Patients Sex Age Hep:ferr 
ratio 
2 M 57 7.48  17 M 65 11.53  
4 M 40 11.88 18 M 48 1.98 
5 M 50 12.98 20 M 60 12.67 
6 M 59 32.71 21 F 69 2.80 
7 F 47 25.64 22 M 60 - 
8 M 52 3.41 23 F 46 3.60 
9 F 55 9.87 24 M 56 - 
10 M 46 6.84 28 M 46 14.06  
11 M 64 13.93 29 M 75 23.43 
13 F 64 10.73 30 M 69 8.63 
15 M 64 21.54 32 F 67 6.7 
16 M 64 21     
 
Figure 6 represent hepcidin:ferritin ratio in our βTT patients as compared to 
normal individuals [Traglia M et al, 2011]. 
 
  
Figure 6: Hepcidin:ferritin ratio in our 
males; square = females) as compared to age
variations in a large sample of n
βTT patients with IO (diamond = 
- and sex-dependent hepcidin 
ormal individuals. 
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As concern Next Generation Sequencing analysis (up to now performed in 28 
patients), it did not reveal potentially pathogenic variants out of the known H63D 
and C282Y in HFE, even in 5 subject with family history for liver disease or iron 
overload (Table 11).  
  
Table 11: Family history for liver disease or hyperferritinemia. 
Patient Family History βTT in relatives 
1 cryptogenic cirrhosis (mother) No 
2 cirrhosis and hyperferritinemia (brother) No  
5 cirrhosis (brother and sister) Yes (brother) 
8 hyperferritinemia (father) Yes 
25 hyperferritinemia (father) No 
 
 
3.2  Patients treated with “mini-phlebotomies”  
Fifteen patients started the treatment with “mini-phlebotomies”. We treated one 
patient also with subcutaneous infusion of DFO, considered the degree of anemia 
(basal Hb 9-10 g/dl) and the severity of iron overload (ferritin 2542 µg/l, 
transferrin saturation 100% and LIC-MRI > 350 µmol/g). Phlebotomies were 
performed until iron depletion, that was achieved when ferritin was in the normal 
range (<300 ng/ml).  Until now, eleven patients have reached the iron depletion. 
None of the patients have experienced a worsening of anemia during the 
treatment. Only one subject temporarily discontinued the treatment because of a 
rapid decline of Hb level, due to a gastrointestinal bleeding (with subsequent 
endoscopic finding of “erosive gastritis Helicobacter Pylori related”). Table 12 
summarizes number and frequency of phlebotomies and the estimated amount of 
iron removed (calculated as shown above).  
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Table 12: Characteristics of treatment with “mini-phlebotomies”. 
Patients Mean 
Ht (%) 
Phlebotomies (ml) and 
frequency 
N° phlebotomies Total 
blood 
removed 
(ml) 
Initial ferritin 
(ng/ml) 
Final ferritin 
(ng/ml) 
Iron removed** 
(g) 
2 n.d. 250 every 7 days 18  3500 962 146 n.d. 
5 n.d. ~175 every 20 days* 22 n.d. 2542 n.d. n.d. 
7 34.2 150 every 7 days 54  8100 735 158 3.2 
9 38.4 ~150 every 15 days 42 7500 1378 261 3.3 
10 33.5 100-150 every 15 days 39 5650 947 322 2.1 
11 41.5 150-200 every 15 days 19 3000 1146 239 1.4 
13 34.7 150 every 15-20 days 16 2400 848 143 0.9 
15 38.6 150 every 15 days 16 2500 644 293 1.1 
16 37.7 150-200 every15days 15 2950 620 302 1.2 
19 34.6 200-250 every 30 days 18 3500 454 256 1.3 
20 41.3 ~250 every 10 days 16 4000 1125 104 1.8 
21 n.d. 150 every 20 days 27 (in progress) - 840 - - 
23 n.d. 150 every 15-20 days 30 (in progress) - 994 - - 
28 n.d. 200 ml every 15-20 days 8 (in progress) - 880 - - 
32 n.d. 250 ml every 10 days 15 (in progress) - 3015 - - 
*plus DFO 20 mg/kg/die. **calculated in agreement with the degree of anemia (Ht) 
 
 
 Although the estimation of iron removed is only 
less than expected in relation to the initial values 
does not seem to have any significant correlation with all iron indices, included 
the transferrin saturation value (Table 13 and Figure 7, 8 an
Table 13: Iron indices in 
to correlate with amount of iron removed.
Patients Initial ferritin 
(ng/ml) 
7 735
9 1378
10 947
11 1146
13 848
15 644
16 620
19 454
20 1125
 
 
Figure 7: No correlation between
approximate, it appears to be 
of ferritin and LIC
d 9). 
 
βTT patients treated with “mini-phlebotomies” seem not 
 
 
TS (%) LIC-MRI 
(µmol/g) 
Iron removed (g)
 28 150 
 46 330 
 100 150 
 53 270 
 65 - 
 40 95 
 52 170 
 66 200 
 25 65 
 initial ferritin value and IR in β
treated with “mini-phlebotomies”. 
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-MRI and 
 
3.1 
3.2 
2.1 
1.4 
0.9 
1.1 
1.2 
1.3 
1.8 
 
TT patients 
 Figure 8: No correlation between
patients treated with “mini
Figure 9: No correlation between
 liver iron concentration at MRI and IR in 
-phlebotomies”. 
 
 
 transferrin saturation and IR in 
treated with “mini-phlebotomies”. 
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βTT 
 
βTT patients 
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4. DISCUSSION 
β-thalassemias are monogenic diseases characterized by the lack or reduction 
of the haemoglobin β-globin chain expression resulting in an increase of the α/β 
globin ratio. The excess free α chains aggregate and precipitate in erythroblasts, 
leading to damage of cell membranes and reactive oxygen species (ROS) 
generation, leading to ineffective erythropoiesis. Ineffective erythropoiesis is 
characterized by an expansion of immature erythroblasts associated with 
apoptosis of mature erythroblasts at the polychromatophilic stage, leading to a 
major reduction of red cell production. In addition, ineffective erythropoiesis of β-
thalassemia is associated with iron overload. Patients with the most severe forms 
(β-thalassemia major) require chronic red blood cell transfusion for survival and 
iron chelation to prevent increased plasma iron and formation of non–transferrin-
bound iron (NTBI) with its related organ damage. 
Patients associated with a milder phenotype (β-thalassemia intermedia or non–
transfusion-dependent thalassemia) may need only sporadic blood transfusions. 
However, because of ineffective erythropoiesis, these patients exhibit increased 
iron absorption and NTBI, leading to severe iron overload, its clinical 
manifestations, and eventually death. In addition, iron overload may further 
aggravate ineffective erythropoiesis by stimulating erythroblast ROS production, 
which increases the α/β-globin chains imbalance. 
β-thalassemia trait with IO represents a relatively neglected and “orphan” 
condition, which can be observed in regions where βTT is prevalent along with 
certain multifactorial modifiers, particularly substantial alcohol intake and H63D 
variant on HFE gene.  
In particular, the role of the H63D heterozygosis in IO determinism has been 
long debated, but recently an interesting study on its impact on the iron status and 
haemoglobin concentration during the developmental age, demonstrated that male 
H63D carriers presented higher blood iron, transferrin saturation and ferritin 
concentration than wild type probands, suggesting that changes in iron 
metabolism occur at young age in HFE heterozygotes, even in normal individuals 
[Barbara KH et al, 2016].  
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For the last decade, investigators have focused on understanding the 
mechanisms underlying iron overload in ineffective erythropoiesis, hypothesizing 
that correction of ineffective erythropoiesis would significantly reduce iron 
overload and improve anemia.  
Hepcidin, a small peptide mainly produced by the liver, is absolutely required 
for the maintenance of systemic iron homeostasis in basal conditions. Hepcidin 
controls serum iron levels by binding to ferroportin (FPN), the only known iron 
exporter, and inducing its degradation. Low hepcidin stabilizes FPN at the cellular 
membrane, promoting dietary iron absorption in the duodenum, increasing the 
release of iron from macrophages following erythrophagocytosis, and enabling 
iron mobilization from hepatocytes. Likewise, hepcidin is suppressed in 
conditions associated with accelerated erythropoiesis (e.g. anemia due to bleeding, 
hemolysis, or iron deficiency) and ineffective erythropoiesis (e.g. β-thalassemia) 
Although our βTT-IO patients display high levels of hepcidin, they show a 
very low hepcidin:ferritin ratio, suggesting that hepcidin response to iron is 
conserved in this subgroup of population but at a lower set point than in normal 
individuals. The inadequate hepcidin response demonstrated by the reduced 
hepcidin:ferritin ratio was in agreement with the findings of previous studies that 
found a reduced hepcidin:ferritin ratio even in subjects without overt iron 
accumulation [Jones E et al, 2015; Guimarães JS et al, 2015; Sulovska L et al, 
2016 ]. 
In 2014, the Ganz laboratory has shown that ERFE, a member of the C1q-
tumor necrosis factor–related family of proteins, is probably the major negative 
regulator of hepcidin in conditions of stress or ineffective erythropoiesis. ERFE is 
produced by erythroid precursors in the bone marrow on erythropoietin (EPO) 
stimulation and represses liver hepcidin production by a still unknown 
mechanism. These data have been confirmed in vitro and in mouse models, but 
still require confirmation in humans, so our population could provide extremely 
useful information about the mechanisms of reciprocal regulation between  
erythropoiesis and iron.  
Preliminary results suggest “mini-phlebotomies” are effective in the removal of 
iron overload and overall well tolerated (none of the patients experienced a 
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worsening of anemia during the treatment), so they appear as a valuable approach 
for this peculiar category of mild anemic patients. However, in most patients, the 
calculated iron removed was less than expected on the basis of initial ferritin 
values and LIC. Concerning ferritin, this may be due to the presence of multiple 
confounders (active alcohol abuse, increased transaminases, DIOS). Magnetic 
resonance is known to overestimate the amount of iron accumulation, especially 
in patients with hepatic steatosis. The study is still ongoing and this point can 
probably be clarified by enrolling a larger number of βTT subjects without 
comorbidity factors. 
In some subjects we observed a slightly increased of mean haemoglobin level 
after iron depletion, suggesting that iron overload may aggravate ineffective 
erythropoiesis. The mechanisms by which this occurs are not completely 
understood, but is known that iron overload inhibits burst-forming unit colony 
formation and erythroblast differentiation of both murine and human 
hematopoietic progenitors in vitro, and cells exposed to excess iron exhibit 
dysplastic changes with increased intracellular ROS and decreased BCL-2 (anti-
apoptotic gene) expression [Taoka K et al, 2012].  
To our knowledge this is the first study that investigated the role of “mini-
phlebotomies” in the treatment of secondary iron overload in patients with mild 
anemia. This approach could be useful in other severely iron-loaded anemic 
patients. 
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